A retrospective analysis of the outcome of radical prostatectomy (RP) for prostate cancer in a single centre and assessment of the role of salvage radiotherapy (RT) for patients with biochemical relapse. Hundred and thirty-seven patients underwent RP for adenocarcinoma of the prostate in our centre between December 1994 and June 2003. Fifty-four of these patients developed a biochemical relapse prostate-specific antigen (PSAX0.2 ng/ml). Thirty-two patients including five from elsewhere (one with a palpable local recurrence) received salvage RT. Twenty-five of these had positive margins at resection and four had involvement of seminal vesicles. Nine had Gleason score X8. Median PSA before RT was 0.55 ng/ml (range 0.2-5.0). Median age at surgery was 63.5 years (range 52-71). Median age at RT was 65 years (range 53-73). Median time from surgery to biochemical relapse was 11 months (range 0-37) and median interval from surgery to RT was 22 months (range 3-71). Twenty-seven patients received 64 Gy in 32 fractions, three patients received 55 Gy in 20 fractions and two patients received 50 Gy in 20 fractions. Twenty-seven patients were managed by observation or hormone therapy. Twenty-seven patients (84%) achieved complete biochemical remission following RT. Eighteen (56%) remain in complete remission with a median follow-up since RT for the whole group of 30 months (range 8-85). Fourteen patients have relapsed, eight of whom had either clear margins or PSA 41.0 ng/ml at the time of RT (PSAX0.2 ng/ml). Salvage RT is an effective treatment for achieving biochemical remission in selected patients who relapse following RP.
Introduction
Excluding skin cancer, prostate cancer is the second most common malignancy in men. Around 22 000 new cases are diagnosed every year in the UK. 1 The number of RP performed annually in the UK increased nearly 20-fold between 1991 and 1999 rising to approximately 800 in 1999. 2 The British Association of Urological Surgeons recorded over 1400 operations performed by 90 surgeons from 55 centres in 2004. 3 Biochemical relapse with rising prostate-specific antigen (PSA) levels following RP is a common problem and occurs in 20-40% of patients within 5 years of surgery. 4, 5 PSA recurrence-free survival estimates for the UK may be less optimistic than values quoted in the American literature. 6 Management in this situation includes salvage radiotherapy (RT), hormonal treatment and observation. There are no randomized clinical trials to indicate which of these approaches is superior.
We have reviewed the outcome of 137 patients treated with RP in a single centre from December 1994 to June 2003 and examined the management of biochemical relapse in this group. We present a review of the management of all 54 patients with biochemical relapse and detail the outcome of 32 patients treated with salvage RT.
Patients and methods
We have retrospectively reviewed the records of 137 consecutive patients who underwent RP in our centre between December 1994 and June 2003. Surgery was performed by three surgeons operating on 100, 32 and five cases, respectively. Patients have usually been followed 3 monthly for the first 2 years and 6 monthly thereafter unless there was evidence of biochemical relapse. Biochemical relapse has been defined as PSAX0.2 ng/ml at any time following surgery. 7 Based on these criteria, 54 patients have relapsed and nine of these never achieved an undetectable PSA. Two developed a palpable local recurrence and four have died from unrelated causes. Biochemical relapse-free survival is presented in Figure 1 . The Kaplan-Meier PSA recurrence-free survival at 3 and 5 years is 63 and 59%, respectively. Clinical and pathological features are presented in Table 1. Since 1996, 27 patients from this centre and a further five cases referred from surgeons elsewhere (including one patient with a palpable local recurrence) were selected for salvage RT which was planned by four consultants treating 27, two, two and one case, respectively.
The median age of these 32 patients at surgery was 63.5 years (range 52-71). Median time from surgery to biochemical relapse was 11 months (range 0-37), and median interval from RP to RT was 22 months (range 3-71). Median time from PSA relapse to commencing RT was 8 months (range 2-49).
No further routine staging was performed. Only one patient had a palpable local recurrence. Median PSA at the time of RT was 0.55 ng/ml (range 0.2-5.0). Twentyfive of 32 patients had positive resection margins following RP. Only four had involvement of seminal vesicles and none had involved lymph nodes. Patients with Gleason score eight or more were not excluded, but patients with a short PSA doubling time were not usually offered salvage RT.
Patients were treated with RT following informed written consent. The majority were treated with a twophase technique initially with three or four fields to the pelvis. Anterior field placement was from lower border of sacroiliac joint to below the ischial tuberosity and 1 cm lateral to the pelvic sidewall. Lateral fields were from the mid-rectum to anterior symphysis pubis. The second phase was delineated on cross-sectional computed tomography (CT) images. Clinical target volume encompassed the reconstructed bladder neck within the prostatic bed and was guided on occasion by surgical clips in the tumour bed. The volume was grown by 10 mm. The field length was usually constrained to minimize the risk of rectal toxicity (median 60 mm; range 50-85) and anterior, and two lateral wedged fields were chosen. The remainder were treated with small fields to the prostatic bed alone. Patients were usually treated with open fields throughout.
The dose delivered was prescribed to the isocentre in keeping with ICRU recommendations. Of the total of 32 patients, 26 received 64 Gy in 32 daily fractions in two phases (phase I -40 Gy in 20 fractions; phase II -24 Gy in 12 fractions). Three men received 55 Gy in 20 daily fractions; two patients received 50 Gy in 20 daily fractions and one patient with inflammatory bowel disease received 64 Gy in 32 fractions, in a single phase to a small volume.
Five patients received neo-adjuvant hormonal therapy with monthly or three monthly depot injections of luteinizing hormone-releasing hormone, which was discontinued after RT, although this is no longer our current practice. One of these had a palpable recurrence and simultaneous renal cancer.
A further 27 patients were identified who have either been followed closely or treated with hormonal therapy following biochemical relapse.
Results
Biochemical relapse-free survival for 32 patients treated with RT is presented in Figure 2 . In 84% of patients, PSA became undetectable 6-8 weeks following RT (o0.1 ng/ ml). Median follow-up since RT is 30 months (range 8-85). The Kaplan-Meier recurrence-free survival at 3 years is 49%.
Six patients treated with local fields achieved a complete response (CR), but only three remain in biochemical remission, including one patient with a palpable local recurrence treated with neo-adjuvant hormones and radical RT who also had a primary renal cell cancer.
Of the six patients who failed to achieve CR following surgery, five achieved initial CR following salvage RT and two remain in remission. Three of seven patients Five patients failed to achieve CR after salvage RT (PSAX0.2 ng/ml). In four of these, the decision to treat was delayed beyond the median of 8 months and these four patients also had negative margins, involved seminal vesicles or both.
Nine patients relapsed after initial CR (PSAX0.2 ng/ ml at anytime following last day of RT). One had negative margins, one had involved seminal vesicles and three had PSA41.0 ng/ml. Time to RT was more than 8 months in a further two patients.
Salvage RT was unsuccessful in all patients with PSA41.5 ng/ml at the time of RT and in eight of 15 patients treated more than 8 months after PSA relapse. Of 14 relapses, five have been treated with anti-androgen therapy including two patients with bone metastases, while the remaining nine remain under observation.
Toxicity was generally mild and manageable following RT. One patient had acute proctitis treated by prednisolone per rectum. One patient has been investigated for rectal bleeding and two for urgency and haematuria. One patient complained of tenesmus. No grade III or IV toxicity has been observed and no cases of incontinence. 8 Of the 27 patients selected for conservative management, 13 have been treated with anti-androgen therapy including two patients with involved lymph nodes at surgery. Median PSA at intervention was 3.1 ng/ml (range 0.5-13.0). Two had a local palpable recurrence, one of whom died of metastatic carcinoma of prostate. Fourteen patients continue to be observed without further therapy. For this group, the median PSA is 0.3 ng/ml (range 0.1-8.3) and median follow-up, since relapse is 32 months (range 0-54).
Discussion
RP has become widely performed in the UK in the past decade. Biochemical relapse following RP is a common problem occurring in 20-40% of patients within 5 years of surgery. 4, 5 Although the clinical significance of a detectable PSA is uncertain, patients experience considerable anxiety and are increasingly referred to radiotherapists for consideration of salvage therapy. About one-third of men undergoing RP for presumed organ confined disease will be found to have positive surgical margins. 9 These patients are at an increased risk of either local or distant recurrence initially identified by a rising PSA. In this series, 54 patients have relapsed following RP (PSAX0.2 ng/ml).
In our experience, the Kaplan-Meier PSA recurrencefree survival probability at 3 and 5 years is 63 and 59% and this compares with 69 and 60% presented in a multicentre audit from the UK. 6 There is no proven role for imaging or biopsies in the diagnosis of local recurrence following RP. Although in one series up to half the patients with a rising PSA had a positive transrectal ultrasonography (TRUS) guided vesico-urethral anastomosis biopsy, 10 other authors have shown that a positive biopsy did not predict an improved outcome after salvage RT. 11 Bone scintigraphy is of no value in this situation. 12 Even in patients with palpable biopsy proven relapse, CT scanning is unlikely to differentiate between recurrence and scar tissue. 13 For patients with localized recurrence following RP, salvage RT offers the only potential chance of cure for patients with isolated local recurrence. Early studies with small patient numbers were associated with disappointing results, largely because of poor selection of patients including those with a high risk of disseminated disease. 14, 15 The largest published retrospective multicentre study of salvage RT, with 501 patients, has shown that a high pre-RT PSA level, negative surgical margins, high Gleason score, [8] [9] [10] seminal vesicle involvement and a short PSA doubling time (p10 months) are associated with a poor prognosis and suggest the presence of distant metastases. 16 Our practice has gradually evolved since the first patient was treated in 1996 and selection for salvage RT or observation in part reflects the preference of the referring surgeon.
We have endeavoured to select patients with a high probability of local relapse for salvage RT. In 84% of the patients, PSA became undetectable following RT. Median PSA at the time of salvage RT was 0.55 ng/ml and the majority of patients had positive surgical margins with an increased risk of local relapse and PSAo1.5 ng/ml in line with the ASTRO consensus panel. 17 Patients with involved lymph nodes have been excluded and usually also patients with involved seminal vesicles or PSA doubling time of less than 6 months. Tighter patient selection reducing the time to salvage and excluding those with negative margins or PSA41.0 ng/ml would have significantly reduced the probability of relapse post RT.
Six patients with positive margins, but no evidence of metastatic disease, completed immediate salvage RT as their PSA levels remained detectable following surgery. Two remain in biochemical remission. Five early patients were treated with neo-adjuvant hormones, but this is no longer our practice.
The volume to be treated in this situation is poorly defined. Although in one series the majority of relapses identified by TRUS guided biopsy occurred at the anastomotic site, relapse was also identified at the level Patients at risk Figure 2 Biochemical relapse following salvage radiotherapy.
Biochemical failure following radical prostatectomy AD Stockdale et al of bladder neck and posterior to the trigone. 18 The volume and dose chosen by radiation oncologists varies between series and one or two phase techniques are described. 16, 19 We have chosen a pragmatic approach usually treating a small pelvic field before coning down to the prostatic bed. The final volume has been delineated on cross-sectional CT slices to encompass the reconstructed bladder neck. Surgical clips may assist in identifying the previous site of the apex of the prostate and the upper border is around the superior aspect of the symphysis pubis.
Although salvage RT is usually well tolerated this is likely to be dependent on dose and technique. Significant grade III and IV bladder toxicity has been described following treatment delivered with a rotating-arch technique to a dose of 50-55 Gy in 16-20 fractions. 20 We have been conservative in our choice of dose and fractionation following the recommendation of the ASTRO consensus panel, choosing a dose of 64 Gy in 2-Gy fractions. 17 We have restricted the use of RT to salvage following biochemical relapse and have seen no grade III or IV late toxicity or incontinence.
Although a survey of UK clinical oncologists indicates that salvage RT is routinely offered to patients, 21 we are aware of only one other series from the UK. 22 There are significant differences between our own practice and that of our colleagues in Manchester who chose a hypofractionated regime. They treated a more advanced group with a positive magnetic resonance imaging scan or palpable disease in just over half the patients, involved seminal vesicles in 21% of patients and a median PSA of 2.9 ng/ml.
They also chose to use the ASTRO consensus guidelines to define biochemical failure following radical RT. Only 39% of patients in this less-selective series achieved the more stringent end point of an undetectable PSAo0.1 ng/ml compared with 84% in our own series. Our own results are comparable to those in the American literature 16 and could probably have been improved with tighter patient selection. Approximately half remain in remission 3 years after RT.
We have, however, also identified a group of patients who remain under observation with a median PSA of only 0.3 ng/ml after a median follow-up of 32 months since relapse. This is perhaps as a consequence of residual benign prostatic tissue and such patients are unlikely to benefit from salvage RT. Some would argue that PSA40.4 ng/ml may be a better cut-off for salvage treatment. 23 Appropriate management of patients relapsing following RP remains uncertain, but there is clear evidence that results with RT are poor if treatment is delayed and patients are not carefully selected. In the absence of any proven survival advantage we believe that treatment should be reserved for younger patients most likely to benefit and for high-grade cases most likely to die from prostatic cancer in a shorter time.
A recent randomized trial has shown improved local control and biochemical progression-free survival, for patients with pT 3 disease or positive surgical margins following adjuvant RT. 24 However, the Kaplan-Meier estimate of 5-year biochemical relapse-free survival in this series was over 50% for patients receiving no adjuvant therapy, resulting in over half the patients receiving unnecessary treatment.
We believe that these results justify our current practice of early salvage RT for biochemical relapse in patients with pT 3 disease or positive margins. Patients with pT2 disease, negative margins or involved lymph nodes are probably best not treated with RT.
The proposed RADICALS (MRC PR10) trial will include a comparison between immediate RT and deferred salvage RT following RP and will also look at the role if any, and duration of anti-androgen therapy. It should provide some much needed answers in this increasingly common clinical situation.
Conclusions
Salvage RT for selected patients experiencing biochemical relapse after RP offers a high probability of durable biochemical remission and the potential for cure with a low risk of morbidity. Prolonged follow-up will be necessary to show any potential survival benefit. Clinical trials are needed to clarify patient selection and choice of adjuvant or salvage RT as well as dose fractionation and volume to treat.
